186 related articles for article (PubMed ID: 23790467)
1. Pharmacokinetic/pharmacodynamic modelling-based optimisation of administration schedule for the histone deacetylase inhibitor abexinostat (S78454/PCI-24781) in phase I.
Fouliard S; Robert R; Jacquet-Bescond A; du Rieu QC; Balasubramanian S; Loury D; Loriot Y; Hollebecque A; Kloos I; Soria JC; Chenel M; Depil S
Eur J Cancer; 2013 Sep; 49(13):2791-7. PubMed ID: 23790467
[TBL] [Abstract][Full Text] [Related]
2. Phase 1 study of oral abexinostat, a histone deacetylase inhibitor, in combination with doxorubicin in patients with metastatic sarcoma.
Choy E; Flamand Y; Balasubramanian S; Butrynski JE; Harmon DC; George S; Cote GM; Wagner AJ; Morgan JA; Sirisawad M; Mani C; Hornicek FJ; Duan Z; Demetri GD
Cancer; 2015 Apr; 121(8):1223-30. PubMed ID: 25536954
[TBL] [Abstract][Full Text] [Related]
3. Application of hematological toxicity modeling in clinical development of abexinostat (S-78454, PCI-24781), a new histone deacetylase inhibitor.
Chalret du Rieu Q; Fouliard S; Jacquet-Bescond A; Robert R; Kloos I; Depil S; Chatelut E; Chenel M
Pharm Res; 2013 Oct; 30(10):2640-53. PubMed ID: 23737346
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 study of the oral histone deacetylase inhibitor abexinostat in patients with Hodgkin lymphoma, non-Hodgkin lymphoma, or chronic lymphocytic leukaemia.
Morschhauser F; Terriou L; Coiffier B; Bachy E; Varga A; Kloos I; Lelièvre H; Sarry AL; Depil S; Ribrag V
Invest New Drugs; 2015 Apr; 33(2):423-31. PubMed ID: 25600050
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic/Pharmacodynamic modeling of abexinostat-induced thrombocytopenia across different patient populations: application for the determination of the maximum tolerated doses in both lymphoma and solid tumour patients.
Chalret du Rieu Q; Fouliard S; White-Koning M; Kloos I; Chatelut E; Chenel M
Invest New Drugs; 2014 Oct; 32(5):985-94. PubMed ID: 24875134
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting Histone Deacetylase as a Means to Reverse Resistance to Angiogenesis Inhibitors: Phase I Study of Abexinostat Plus Pazopanib in Advanced Solid Tumor Malignancies.
Aggarwal R; Thomas S; Pawlowska N; Bartelink I; Grabowsky J; Jahan T; Cripps A; Harb A; Leng J; Reinert A; Mastroserio I; Truong TG; Ryan CJ; Munster PN
J Clin Oncol; 2017 Apr; 35(11):1231-1239. PubMed ID: 28221861
[TBL] [Abstract][Full Text] [Related]
7. A Phase I/II Multicenter, Open-Label Study of the Oral Histone Deacetylase Inhibitor Abexinostat in Relapsed/Refractory Lymphoma.
Evens AM; Balasubramanian S; Vose JM; Harb W; Gordon LI; Langdon R; Sprague J; Sirisawad M; Mani C; Yue J; Luan Y; Horton S; Graef T; Bartlett NL
Clin Cancer Res; 2016 Mar; 22(5):1059-66. PubMed ID: 26482040
[TBL] [Abstract][Full Text] [Related]
8. A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate histone deacetylase inhibitor with evidence of target modulation and antitumor activity, in patients with advanced solid tumors.
Venugopal B; Baird R; Kristeleit RS; Plummer R; Cowan R; Stewart A; Fourneau N; Hellemans P; Elsayed Y; McClue S; Smit JW; Forslund A; Phelps C; Camm J; Evans TR; de Bono JS; Banerji U
Clin Cancer Res; 2013 Aug; 19(15):4262-72. PubMed ID: 23741066
[TBL] [Abstract][Full Text] [Related]
9. Phase 1 dose-escalation study of oral abexinostat for the treatment of patients with relapsed/refractory higher-risk myelodysplastic syndromes, acute myeloid leukemia, or acute lymphoblastic leukemia.
Vey N; Prebet T; Thalamas C; Charbonnier A; Rey J; Kloos I; Liu E; Luan Y; Vezan R; Graef T; Recher C
Leuk Lymphoma; 2017 Aug; 58(8):1880-1886. PubMed ID: 27911138
[TBL] [Abstract][Full Text] [Related]
10. Phase I and pharmacokinetic study of MS-275, a histone deacetylase inhibitor, in patients with advanced and refractory solid tumors or lymphoma.
Ryan QC; Headlee D; Acharya M; Sparreboom A; Trepel JB; Ye J; Figg WD; Hwang K; Chung EJ; Murgo A; Melillo G; Elsayed Y; Monga M; Kalnitskiy M; Zwiebel J; Sausville EA
J Clin Oncol; 2005 Jun; 23(17):3912-22. PubMed ID: 15851766
[TBL] [Abstract][Full Text] [Related]
11. A phase I first-in-human study with tefinostat - a monocyte/macrophage targeted histone deacetylase inhibitor - in patients with advanced haematological malignancies.
Ossenkoppele GJ; Lowenberg B; Zachee P; Vey N; Breems D; Van de Loosdrecht AA; Davidson AH; Wells G; Needham L; Bawden L; Toal M; Hooftman L; Debnam PM
Br J Haematol; 2013 Jul; 162(2):191-201. PubMed ID: 23647373
[TBL] [Abstract][Full Text] [Related]
12. Phase I and pharmacokinetic study of triapine, a potent ribonucleotide reductase inhibitor, administered daily for five days in patients with advanced solid tumors.
Murren J; Modiano M; Clairmont C; Lambert P; Savaraj N; Doyle T; Sznol M
Clin Cancer Res; 2003 Sep; 9(11):4092-100. PubMed ID: 14519631
[TBL] [Abstract][Full Text] [Related]
13. First-in-human study of the toxicity, pharmacokinetics, and pharmacodynamics of CG200745, a pan-HDAC inhibitor, in patients with refractory solid malignancies.
Kim KP; Park SJ; Kim JE; Hong YS; Lee JL; Bae KS; Cha H; Kwon SK; Ro S; Cho J; Kim TW
Invest New Drugs; 2015 Oct; 33(5):1048-57. PubMed ID: 26076682
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of abexinostat, a pan-histone deacetylase inhibitor, in non-Hodgkin lymphoma and chronic lymphocytic leukemia: results of a phase II study.
Ribrag V; Kim WS; Bouabdallah R; Lim ST; Coiffier B; Illes A; Lemieux B; Dyer MJS; Offner F; Felloussi Z; Kloos I; Luan Y; Vezan R; Graef T; Morschhauser F
Haematologica; 2017 May; 102(5):903-909. PubMed ID: 28126962
[TBL] [Abstract][Full Text] [Related]
15. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
[TBL] [Abstract][Full Text] [Related]
16. A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia.
Gimsing P; Hansen M; Knudsen LM; Knoblauch P; Christensen IJ; Ooi CE; Buhl-Jensen P
Eur J Haematol; 2008 Sep; 81(3):170-6. PubMed ID: 18510700
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of safety, pharmacokinetics, and efficacy of vorinostat, a histone deacetylase inhibitor, in the treatment of gastrointestinal (GI) cancer in a phase I clinical trial.
Doi T; Hamaguchi T; Shirao K; Chin K; Hatake K; Noguchi K; Otsuki T; Mehta A; Ohtsu A
Int J Clin Oncol; 2013 Feb; 18(1):87-95. PubMed ID: 22234637
[TBL] [Abstract][Full Text] [Related]
18. Phase-I dose escalation and sequencing study of docetaxel and continuous infusion topotecan in patients with advanced malignancies.
Posey JA; Wang H; Hamilton J; Delgrosso A; Zhang R; Freda T; Zamboni WC
Cancer Chemother Pharmacol; 2005 Aug; 56(2):182-8. PubMed ID: 15838660
[TBL] [Abstract][Full Text] [Related]
19. Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.
DeAngelo DJ; Spencer A; Bhalla KN; Prince HM; Fischer T; Kindler T; Giles FJ; Scott JW; Parker K; Liu A; Woo M; Atadja P; Mishra KK; Ottmann OG
Leukemia; 2013 Aug; 27(8):1628-36. PubMed ID: 23385375
[TBL] [Abstract][Full Text] [Related]
20. A phase I dose-escalation study of intravenous panobinostat in patients with lymphoma and solid tumors.
Sharma S; Beck J; Mita M; Paul S; Woo MM; Squier M; Gadbaw B; Prince HM
Invest New Drugs; 2013 Aug; 31(4):974-85. PubMed ID: 23377661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
